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Many antimalarial drugs kill malaria parasites, but antimalarial drug resistance (ADR) and toxicity to nor-
mal cells limit their usefulness. To solve this problem, we suggest a new therapy for drug-resistant
malaria. The approach consists of data integration and inference through homology analysis of
yeast–human–Plasmodium. If one gene of a Plasmodium synthetic lethal (SL) gene pair has a mutation that
causes ADR, a drug targeting the other gene of the SL pair might be used as an effective treatment for
drug-resistant strains of malaria. A simple computational tool to analyze the inferred SL genes of
Plasmodium species (malaria parasites Plasmodium falciparum and Plasmodium vivax for human malarial
therapy, and rodent parasite Plasmodium berghei for in vivo studies of human malarias) was established to
identify SL genes that can be used as drug targets. Information on SL gene pairs with ADR genes and their
ﬁrst neighbors was inferred from yeast SL genes to search for pertinent antimalarial drug targets. We not
only suggest drug target gene candidates for further experimental validation, but also provide informa-
tion on new usage for already-described drugs. The proposed speciﬁc antimalarial drug candidates can be
inferred by searching drugs that cause a ﬁtness defect in yeast SL genes.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
Malaria is one of the most serious causes of morbidity and mor-
tality in tropical regions. The World Health Organization recently
estimated that malaria causes about 240 million bouts of illness
and around 0.86 million deaths annually (http://www.who.int/
mediacentre/factsheets/fs094/en/print.html, world health
organization malaria fact sheet No. 94, 2010). Several Plasmodium
species (P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi)
have been identiﬁed to be responsible for a signiﬁcant number of
human malaria infections in Southeast Asia. Among these species,
P. falciparum is the most severe and responsible for about 90% of
malaria deaths (Cox-Singh et al., 2008), predominantly in Africa
(Eisenstein, 2012).P. vivax has a considerably lower mortality rate but a far greater
geographical distribution. It causes widespread malaria outside
Africa, mainly afﬂicting Asia and the Americas (Price et al., 2007).
The human malaria parasite P. vivax is responsible for 25–40% of
the annual bouts of malaria worldwide. Although infection by
the parasite is seldom fatal, such infection induces severe, debili-
tating clinical symptoms and often causes relapses months after
a primary infection is cleared. Despite being a major human path-
ogen, studies on P. vivax are very limited compared with P. falcipa-
rum because P. vivax is not contagiously propagated in the
laboratory and in vitro culture is not amenable (Carlton et al.,
2008).
The major problem with the currently available antimalarial
drugs is that some malaria parasites have continuously developed
resistance to these drugs. Several special treatments for speciﬁc
malarial strains have been introduced. However, the parasites have
become increasingly resistant to conventional antimalarial drugs,
thereby increasing morbidity and mortality. Numerous malarial
drugs kill malaria parasites, but antimalarial drug resistance
(ADR) and toxicity to normal cells limit their usefulness. Such
emerging drug resistance and a lack of effective vaccines require
urgent discovery of new antimalarial drugs and vaccines against
malarial parasites (Anderson, 2009; Huthmacher et al., 2010). Most
malaria researchers are eager to identify and act on drug target
Fig. 2. Information diagram showing the basic concept of searching for drug targets
for use in malarial therapy and a new SL therapy for the elimination of antimalarial
drug-resistant Plasmodium. Information diagram of the basic concept of a drug
target search for malarial therapy. In this study, the phylogenetic inference of
synthetic lethal (SL) genes extracted from yeast and malaria parasites was utilized
for pharmacologic purposes because most existing SL data are restricted to yeast
screenings. SL pairs with human orthologs were not considered.
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determine. Currently, the systematic disruption of every gene in
Plasmodium is technically difﬁcult. A computational approach to
prioritizing potential drug targets was recently established (Yeh
et al., 2004). As massive screening methods, bioinformatics and
computational approaches play predominant roles in drug design.
Nevertheless, a novel strategy is required to overcome the techno-
logical limitations encountered by the current single-drug ap-
proach for effective treatments (Fernández et al., 2009).
We therefore investigated targeting synthetic lethal (SL) gene
pairs as an alternative antimalarial drug therapy. When the
mutation of either component of a gene pair is not lethal but the
mutation of both leads to death or a signiﬁcant decrease in the ﬁt-
ness of the organism, the two genes are called synthetic lethal
(Conde-Pueyo et al., 2009). Fig. 1 represents the rationale for SL
applications in antimalarial therapy. Given that malarial parasites
exhibit various types of drug resistance, the identiﬁcation of proper
SL gene partners may be helpful in ﬁnding speciﬁc antimalarial
drug targets. Such identiﬁcation provides new insights into the de-
sign of a selective antimalarial therapy by exploiting SL partners
that have ADR genes. By ﬁltering out the SL targets that have ana-
logues of the human proteome, minor damage is expected in the
human cell, as shown in the conceptual schematics of selective
antimalarial therapy (Fig. 1). Therefore, this method would be
helpful in dramatically overcoming the limitations in the design
of a suitable malarial drug. However, large-scale screenings for SL
gene pairs have been performed mostly in yeast (Forsburg, 2001;
Pan et al., 2004; Ooi et al., 2006; Boone et al., 2007), and to a lesser
extent in Caenorhabitis elegans (Jorgensen and Mango, 2002; Baugh
et al., 2005; Lehner et al., 2006) and other organisms. Screening re-
search on Plasmodium SL gene pairs has yet to be accomplished.
Consequently, we investigated Plasmodium SL gene pair candi-
dates in the present study using inference methods. Fig. 2 shows
the basic concept of searching for drug targets for antimalarial
therapy. SL screening in yeast is often used to identify the genes in-
volved in cell polarity, secretion, DNA repair, and the cell cycleFig. 1. Rationale for SL applications in antimalarial therapy. Rationale for synthetic leth
lethal (SL) if the mutation of either gene alone is compatible with viability; the mutation
both the malaria parasite and the human cell. (B) If one gene of the SL pair is mutated and
SL partners are inactivated in the malaria parasite, the parasite is selectively damaged.(Tong et al., 2001, 2004). Considering the high conservation of gen-
ome integrity and cell cycle-related genes from yeast to higher
organisms (Yuen et al., 2007), a massive screening for yeast SL
interactions may provide information on using SL inference to
search for novel malarial therapies. The present study aimed not
to discuss the general inference method for the SL network from
one organism to another, but to present the rationale for drug de-
sign by supplying suitable Plasmodium SL gene pairs that can be
used as a potential basis for future pharmacologic tests. Another
objective was to provide an excellent framework for handling very
large genetic systems. In particular, studies on genetic diseases
(Goh et al., 2007; Platzer et al., 2007), gene targets (Yildirim
et al., 2007), and SL networks (Boone et al., 2007; Paladugu et al.,
2008; Chipman and Singh, 2009) have contributed to the under-
standing of these systems as a whole. In the present study, networkality applied in the design of novel antimalarial therapies. Two genes are synthetic
of both leads to death. (A) Single gene targeting is more likely to express toxicity in
the other SL partner is not mutated, the human cells would not die. However, if both
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the reliability of the supplied candidates.
2. Materials and methods
Potential antimalarial drug target genes were identiﬁed by inte-
grating whole biological information from many databases. Fig. 3
illustrates the methodology used for data collection and the selec-
tion of potential antimalarial drug target genes. The phylogeneti-
cally inferred Plasmodium SL gene network was reconstructed by
using phylogenetic analysis and database manipulation to search
for potential antimalarial drug targets. The databases used include
BioGRID (Biological General Repository for Interaction Datasets)
(http://thebiogrid.org) for yeast SL genes, KEGG SSDB (Kyoto Ency-
clopedia of Genes and Genomes Sequence Similarity DataBase)
(http://www.genome.jp/kegg), KEGG OC (Ortholog Cluster)
(http://www.genome.jp/tools/oc) (Nakaya et al., 2013), PlasmoDB
Version 9.1 (http://plasmodb.org), and Gene DB (http://www.ge-
nedb.org) for Plasmodium genes. The inferred Plasmodium SL net-
works were constructed using Cytoscape (version 2.8.1)
(Shannon et al., 2003).
2.1. Inference of Plasmodium SL genes from yeast SL genes
The list of yeast SL gene pairs was obtained from the
‘BIOGRID-ALL-3.1.72.tab2’ data source provided by the BioGRID
database. The collected data on yeast genetic screens included syn-
thetic lethality. The yeast SL network was constructed using the
yeast SL pairs. Then, three Plasmodium species (P. falciparum, P. vi-
vax, and P. berghei) SL gene networks were inferred from the yeast
SL gene data. Plasmodium–yeast gene ortholog data were obtained
from the ortholog information in the KEGG SSDB. Among the yeast
genes (14,548 genes in total), approximately 29% were SL genes
(4,284 genes). Plasmodium gene information, such as gene expres-
sion levels and stages, were obtained from the PlasmoDB version
9.1 (PlasmoDB: http://plasmodb.org/plasmo/webcite, Aug. 31,
2012).
2.2. Extraction of ADR genes from inferred Plasmodium SL genes
We identiﬁed eight P. falciparum ADR genes (PfABC, PfCRT,
PfDHFR-TS, PfDHPS, PfMT, PfMDR1, PfMDR2, and PfNHE1) through
a systematic literature survey (Wilson et al., 1989; Foote et al.,
1990; Wellems et al., 1990; Cowman et al., 1991, 1994; PeelFig. 3. Schematic diagram of the synthetic lethal (SL) gene identiﬁcation methodolog
PlasmoDB were integrated. To search for potential antimalarial drug targets, the infer
database manipulation. The databases employed in this study were BioGRID for yeast Set al., 1993, 1994; Zalis et al., 1993; Rubio and Cowman, 1996;
Reed et al., 2000; Mutabingwa et al., 2001; Sibley et al., 2001;
Giancarlo et al., 2009; Briolant et al., 2012). By phylogenetic infer-
ence, four ADR genes (PfDHFR-TS, PfMDR1, PfMDR2, and PfNHE1)
were discovered to contain the inferred SL genes. PfDHFR-TS exhib-
its a homologous relation with YBR205W and YOR074C. Pfmdr1 has
a homologous relation with YKL209C, YGR281W, YKL188C, and
YLL048C. PfMDR2 has a homologous relation with YMR301C.
PfNHE1 has a homologous relation with YHR081W and YDR456W.
Detailed information is included in Supplementary ﬁle 1.
2.3. Search for Plasmodium genes without similarity to human genes
We searched for information about protein similarities in the
Protein Data Bank (PDB) provided by PlasmoDB. Plasmodium genes
which do not have protein similarities to human genes were se-
lected. The protein structure data in the PDB have been used ac-
tively in the studies of protein function, evolution, and structure
prediction (Bernstein et al., 1977; Noguchi and Akiyama, 2003).
Information on the Plasmodium genes which do not have human
orthologs was obtained from the KEGG OC database. Detailed
information is included in Supplementary ﬁle 2.
2.4. Search for drug candidates
Fitness data from the Yeast Fitness DB (http://ﬁtdb.stanford.
edu, 2012) (Hillenmeyer et al., 2008, 2010) on the yeast homolo-
gous genes of the selected Plasmodium genes were searched to ﬁnd
new drugs for the clinical treatment of malaria. A list of drug can-
didates was obtained through the top three experiments that gave
rise to a ﬁtness defect in yeast genes by heterozygous or homozy-
gous deletion. To utilize the yeast drugs provided by the FitDB, we
conjectured the possibility of evolutionary conservation between
the yeast genes and Plasmodium homologs by identifying protein
similarities in the PDB. From the list of drug candidates, we se-
lected the ﬁnal drug candidates by ﬁltering out the compounds
which do not exist in the DrugBank 3.0 database (http://
www.drugbank.ca) (Knox et al., 2011). A detailed report is avail-
able in Supplementary ﬁle 3.
2.5. Statistical analysis of gene function
The networks associated with gene ontology (GO) annotation
(GOA) terms were statistically analyzed using BINGO 2.44y. Biological information from different databases including BioGRID, KEGG, and
red Plasmodium SL gene network was reconstructed by phylogenetic analysis and
L genes, as well as KEGG and PlasmoDB for Plasmodium genes.
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determining statistically over-represented GO categories in a set of
genes or subgraphs of a biological network. P. falciparum GOA data
were obtained using BINGO. The GO biological process, molecular
functions, and cellular components were selected from the ontol-
ogy list, whereas P. falciparum was selected from the organism list.
Finally, the over-represented GO categories were analyzed using
Cytoscape. The gene functions of the inferred P. falciparum SL
genes, as well as the ADR genes and their ﬁrst neighbors, were ana-
lyzed from the inferred P. falciparum gene networks using BINGO.
The signiﬁcance of their cellular components, molecular func-
tions, and biological processes was evaluated using a hypergeo-
metric test, in which the Benjamini and Hochberg false discovery
rate with a P value less than 0.05 was used as the minimum cutoff
threshold. Using this method, only 608 genes out of a total of 1,423
inferred P. falciparum SL genes were found to be associated with
GOA terms. Only 23 genes out of 50 ADR genes and their ﬁrst
neighbors extracted from the inferred P. falciparum gene network
were associated with GOA terms. The extracted list of genes related
to speciﬁc GOA terms is available in Supplementary ﬁle 4. In addi-
tion, we analyzed the gene functions of the genes selected ADR
genes and their ﬁrst neighbors from the inferred Plasmodium gene
network using the Plasmodium genomics resource in the PlasmoDB.
A detailed report including the list of genes related to speciﬁc GOA
terms is available in Supplementary ﬁles 2 and 3.3. Results
3.1. Inference of Plasmodium SL genes from yeast SL genes
We inferred human and Plasmodium SL gene pairs from yeast
SL gene pairs. A total of 4284 yeast SL genes were obtained from
the BioGRID database (version 3.1.72, http://thebiogrid.org). We
then inferred the Plasmodium (P. falciparum, P. vivax, and P.
berghei) SL gene pairs from the yeast SL gene pairs using the KEGG
database. The inferred P. falciparum, P. vivax, and P. berghei SL
networks are composed of 1536 nodes and 7600 links, 1449 nodes
and 6458 links, as well as 1299 nodes and 7608 links,
respectively.
3.2. Extraction of ADR genes from inferred Plasmodium SL genes
Due to mutations in ADR genes, some antimalarial are not
effective in certain patients. Through a literature survey, we
identiﬁed eight ADR genes: P. falciparum ABC Transporter (PfABC),
P. falciparum putative metabolite/drug transporter (PfMT), P. falci-
parum dihydropteroate synthase (PfDHPS), P. falciparum multidrug
resistance 1 (PfMDR1), P. falciparum multidrug resistance 2
(PfMDR2), P. falciparum sodium/hydrogen exchanger 1 (PfNHE1),
P. falciparum dihydrofolate reductase-thymidylate synthase
(PfDHFR-TS), and P. falciparum chloroquine-resistance transporter
gene (PfCRT) (Wilson et al., 1989; Foote et al., 1990; Wellems
et al., 1990; Cowman et al., 1991; Peel et al., 1993, 1994; Zalis
et al., 1993; Cowman et al., 1994; Rubio and Cowman, 1996; Reed
et al., 2000; Mutabingwa et al., 2001; Sibley et al., 2001; Giancarlo
et al., 2009; Briolant et al., 2012). Four genes (PfMDR1, PfMDR2,
PfDHFR-TS, and PfNHE1) among the eight P. falciparum ADR genes
are inferred as Plasmodium SL genes.
3.3. Extraction of of ADR genes’ SL partners
The SL partners of the ADR genes were extracted from the yeast
SL gene pairs. Fig. 4A and B show typical combinations of Plasmo-
dium SL pairs inferred from the yeast SL pairs. Each entry in the
homology data ﬁle contains the gene’s evolutionary history, whichcorresponds to a gene tree diverging from a common ancestor
(Conde-Pueyo et al., 2009). In this study, the gene conservation
relations in yeast and Plasmodium are categorized into three types.
The simplest is the one-to-one relation between yeast and Plasmo-
dium genes (orthologous relation). However, evolutionary duplica-
tion events lead to two alternative types; one yeast gene has more
than one Plasmodium homolog (one-to-m relation), and vice versa
(n-to-one relation). The n-to-m relation corresponds to the case
where n Plasmodium genes are homologs of m yeast genes
(Sonnhammer and Koonin, 2002). The Plasmodium genes selected
in this study have one-to-one and one-to-n (Plasmodium to yeast)
relations. These relations include auto-loop genes (marked x in
Fig. 4) as SL partners; when an SL pair was composed of the same
single Plasmodium gene, we deﬁned it as an ‘auto-loop gene’. We
discovered four auto-loop genes in P. falciparum, one in P. vivax,
and two in P. berghei from the inferred SL networks composed of
ADR genes and their SL partners. The auto-loop nodes are repre-
sented as yellow background genes in Supplementary ﬁle 1. In this
study, the SL pairs containing auto-loop genes were excluded from
the list of drug target candidates.
3.4. Networks consisting of ADR genes and their SL partners
Fig. 4C shows the networks composed of four ADR genes and
their inferred SL partners as inferred from the yeast SL gene net-
works. Detailed information is given in Supplementary ﬁles 1.
The inferred SL networks composed of ADR genes and their SL part-
ners have 50 nodes and 86 links in P. falciparum, 17 nodes and 27
links in P. vivax, as well as 15 nodes and 19 links in P. berghei. Octa-
gons denote ADR-related nodes and circles indicate their SL part-
ners. The links connecting the ADR genes are depicted as blue
lines. PfNHE1, PfMDR1, PfMDR2 and PfDHFR-TS are four representa-
tive ADR genes inferred as SL genes. Red indicates the PfMDR1 gene
and its inferred SL partners, yellow represents the PfDHFR-TS gene
and its inferred SL partners, green indicates the PfMDR2 gene and
its inferred SL partners, and blue indicates the PfNHE1 gene and
its inferred SL partners. PF11_0192 (orange circle) is the inferred
SL partner of the PfMDR1 (red octagon) and PfDHFR-TS (yellow
octagon) genes. Four ADR genes and their 46 SL partners were ex-
tracted from the inferred P. falciparum SL gene network. Mean-
while, 4 ADR genes and 13 SL partners were selected from the
inferred P. vivax network, whereas four ADR genes and 11 partners
were extracted from the inferred P. berghei network. Detailed func-
tional information on the drug target candidates selected from the
PlasmoDB are summarized and provided in Table 1 and Supple-
mentary ﬁle 2. In this study, we selected genes which do not have
protein similarities between Plasmodium genes and their human
orthologs. Interestingly, almost all of the selected genes are con-
nected to interrelated biological functions, such as ATPase activity,
ATP binding, and ion transportation.
In Table 1, we compare the GO terms of yeast SL genes with that
of the Plasmodium SL genes inferred from yeast SL gene pairs. The
GO terms of PFD0830w, PVX_089950, and PB000415.02.0
(Plasmodium homologous genes of ADR gene- PfDHFR-TS) match
the GO terms of YOR074C (yeast homolog gene of PFD0830w,
PVX_089950, and PB000415.02.0) well. Their biological process is
the dTMP biosynthetic process and their molecular function is thy-
midylate synthase activity. The GO terms of the biological process,
molecular function, and cellular component of PVX_118100 (P.
berghei homologous genes of ADR gene: PfMDR2) and YMR301C
(yeast homologous gene of PVX_118100) are particularly well
matched. Their biological process is transmembrane transport
and their molecular function is ATPase activity. In addition, the cel-
lular component is an integral factor to the membrane, and the GO
terms of the biological process (glutathione biosynthetic process)
and the molecular function (glutamate–cysteine ligase activity)
Fig. 4. Networks of ADR genes and their SL partners extracted from the inferred Plasmodium SL genes. Plasmodium SL gene pairs were inferred from yeast SL pairs. In this
network, nodes represent genes and the link between them indicates an SL interaction. When both are simultaneously mutated, an SL condition is satisﬁed. Gene
conservation between Plasmodium and yeast can be categorized into two types of relations. The simplest case is a one-to-one relation between Plasmodium and yeast genes
(orthologous relation). However, duplication events during evolution cause a one-to-n relation in which two or more yeast genes are homologous to one Plasmodium gene.
(A) For example, the one-to-one case corresponds to one yeast gene having one Plasmodium homolog; the SL pairs Y1 and Y2 correspond to SL pair P1 and P2. In the one-to-n
case, several yeast genes have the same Plasmodium homolog; SL pairs Y1 and Y2 can correspond to only one gene between P1 and P2. In this case, an autolink (auto-loop) is
formed in the network. (B) For yeast SL networks represented by Y3, Y4, and Y5, various relations such as one-to-one, n-to-one, auto-loop, and SL pair-containing auto-loop
genes can be combined. (C) Networks of the four inferred ADR genes in the Plasmodium species. When two SL yeast partners are phylogenetically related to a single
Plasmodium gene, an auto-link appears in the SL network. Single gene targeting is possibly more dangerous than double gene targeting. Therefore, we eliminated the auto-
loop nodes from the drug target candidates and denoted them as red X’s. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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homologous gene of PVX_099360) match each other. In Table 2,
PVX_099360, which is the neighbor gene of PVX_118100 (ADR gene:
PfMDR2), is a putative gamma-glutamylcysteine synthetase.
YJL101C is a yeast homolog gene of PVX_099360. In addition, using
the PlasmoDB, we investigated the similarities of the protein
chains between the yeast and its plasmodium. YJL101C and
PVX_099360 were seen to exhibit protein similarities to
glutamate–cysteine ligase with an identity of 32% and a P value
of 7.6  1064.3.5. Prediction of antimalarial drug targets
To narrow down the list of drug target candidates, we examined
the developmental stages in which Plasmodium genes were ex-
pressed (Supplementary ﬁle 1). In addition, we searched for the
protein similarities within the protein databank (PDB) provided
by the PlasmoDB. These ADR genes and their SL partners extracted
from the inferred Plasmodium SL gene networks can serve as alter-
native antimalarial drug targets for malaria patients with ADR
genes. In addition, we conjectured the possibility of evolutionary
Table 1
Selected antimalarial drug target genes and their GO terms.
Inferred Plasmodium SL genes Plasmodium GO terms Yeast homolog
genes of
Plasmodium
Yeast GO terms
PB000415.02.0 (ADR gene: PfDHFR-TS) Biological Process: dTMP biosynthetic process,
glycine biosynthetic process, one-carbon metabolic
process, nucleotide biosynthetic process, oxidation-
reduction process; Molecular Function:
dihydrofolate reductase activity, thymidylate
synthase activity
YOR074C Biological Process: dTMP biosynthetic process;
Molecular Function: thymidylate synthase
activity; Cellular Component: nucleus
PB000779.01.0 (PB000415.02.0’s
neighbor gene)
Molecular Function: nucleic acid binding, DNA
binding, helicase activity, ATP binding
YDR334W Biological Process: chromatin remodeling, histone
exchange; Molecular Function: structural
molecule activity; Cellular Component: Swr1
complex, nucleus
PFD0830w (ADR gene: PfDHFR-TS) Biological Process: dTMP biosynthetic process,
glycine biosynthetic process, one-carbon metabolic
process, nucleotide biosynthetic process, oxidation-
reduction process; Molecular Function:
dihydrofolate reductase activity, thymidylate
synthase activity
YOR074C Biological Process: dTMP biosynthetic process;
Molecular Function: thymidylate synthase
activity; Cellular Component: nucleus
PF08_0048 (PFD0830w’s neighbor
gene)
Molecular Function: nucleic acid binding, DNA
binding, helicase activity, ATP binding, ATP-
dependent helicase activity
YDR334W Biological Process: chromatin remodeling, histone
exchange; Molecular Function: structural
molecule activity; Cellular Component: Swr1
complex, nucleus
PVX_089950 (ADR gene: PfDHFR-TS) Biological Process: dTMP biosynthetic process,
glycine biosynthetic process, one-carbon metabolic
process, nucleotide biosynthetic process,
oxidation–reduction process; Molecular Function:
dihydrofolate reductase activity, thymidylate
synthase activity
YOR074C Biological Process: dTMP biosynthetic process;
Molecular Function: thymidylate synthase
activity; Cellular Component: nucleus
PVX_089365 (PVX_089950’s neighbor
gene)
Molecular Function: nucleic acid binding, DNA
binding, helicase activity, ATP binding
YLR085C Biological Process: chromatin remodeling, histone
exchange; Molecular Function: nucleosome
binding; Cellular Component: Swr1 complex,
cytoplasm
PVX_118100 (ADR gene: PfMDR2) Biological Process: transport, transmembrane
transport; Molecular Function: ATP binding, ATPase
activity, nucleoside-triphosphatase activity;
Cellular Component: integral to membrane
YMR301C Biological Process: cellular iron ion homeostasis,
transmembrane transport; Molecular Function:
ATPase activity, coupled to transmembrane
movement of substances; Cellular Component:
integral to membrane, mitochondrial inner
membrane, mitochondrion
PVX_099360 (PVX_118100’s neighbor
gene)
Biological Process: glutathione biosynthetic
process; Molecular Function: glutamate–cysteine
ligase activity
YJL101C Biological Process: glutathione biosynthetic
process, response to cadmium ion, response to
hydrogen peroxide; Molecular Function:
glutamate–cysteine ligase activity; Cellular
Component, cytoplasm, intracellular
In this table, we can see detailed functional information on the drug target candidates. We selected genes which do not have protein similarities between Plasmodium genes
and their human orthologs. Interestingly, almost all of the selected genes are connected to interrelated biological functions, such as ATPase activity, ATP binding, and ion
transportation. In this table, we compare the GO terms of yeast SL genes with that of Plasmodium SL genes inferred from yeast SL gene pairs. In addition, through PlasmoDB,
we investigated similarities to Protein Data Bank chains between the yeast gene and its Plasmodium homolog gene. Although these are examples of similarity in the biological
process, molecular function, or cellular component of Plasmodium evolutionary conserved from yeast, their synthetic lethality might conserve in Plasmodium from yeast in the
same vein.
124 S.J. Lee et al. / International Journal for Parasitology: Drugs and Drug Resistance 3 (2013) 119–128conservation between the yeast genes and Plasmodium homologs
using the same identiﬁcation process involving protein similarities.
We obtained the ﬁve inferred SL partners (marked by red loops in
Fig. 5) having the inferred Plasmodium SL gene networks which
have protein similarities among yeast orthologs and Plasmodium
orthologs. In the three networks, the ﬁltered Plasmodium SL pairs
(ADR genes and their inferred SL partners) do not include human
homologous genes. The ﬁltered Plasmodium SL pairs also do not
have human orthologs in the KEGG OC database.3.6. Analysis of biological function of selected drug targets
We carried out a statistical analysis on the biological function of
the selected drug targets using the BINGO 2.44 program (Maere
et al., 2005). BINGO has been used to determine which GO catego-
ries are statistically over-represented in a set of genes or a subset
of biological networks. We obtained only P. falciparum GO data be-
cause the program provides information on the GO of P. falciparum
genes among the Plasmodium species. Fig. 6 shows the relationshipbetween the biological processes of the PFE0195W and PF13_0019
genes as a typical example of GO term analysis. These genes are
the ADR genes and their ﬁrst neighbors extracted from the inferred
P. falciparum SL networks. Information on the biological functions
of other species (P. vivax and P. berghei) can be obtained from the
PlasmoDB. We analyzed the biological processes, molecular func-
tions, and cellular components of the inferred P. falciparum SL
genes, the inferred ADR genes, and their SL partners. Detailed infor-
mation, including the GO terms, is available in Supplementary ﬁles
2–4. Table 1 summarizes the biological functions of the selected
drug target genes analyzed using the PlasmoDB.3.7. New malarial drug candidates
The ﬁve selected drug target gene pairs are listed in Table 2 and
depicted in Fig. 5. According to the information obtained through
the identiﬁcation of protein similarities, the selected SL genes do
not have human homologous genes. The drug candidates for the
selected drug target genes were inferred from the Yeast Fitness
Table 2
Suggested antimalarial drug target genes and possibility of evolutionary conservation of yeast synthetic lethal genes.
Plasmodium Plasmodium Saccharomyces cerevisiae
ADR gene ADR gene’s inferred SL partner Similarities to Protein Data Bank Chains (ADR gene’s
inferred SL partner)
PB000415.02.0 (ADR gene: PfDHFR-TS)/bifunctional
dihydrofolate reductase-thymidylate synthase,
putative
PB000779.01.0 (PB000415.02.0’s neighbor
gene)/Snf2-related CBP activator, putative
Chromo domain-containing protein 1 (% of PlasmoDB
protein Covered: 42;% Identity: 32; P-value: 2.5  1078)
PFD0830w (ADR gene: PfDHFR-TS)/bifunctional
dihydrofolate reductase-thymidylate synthase
PF08_0048 (PFD0830w’s neighbor gene)/Snf2-
related CBP activator, putative
Chromo domain-containing protein 1 (% of PlasmoDB
protein Covered: 34;% Identity: 33; P-value: 1.5  1075)
PF13_0019 (ADR gene: PfNHE1)/sodium/hydrogen
exchanger, Na, H antiporter
MAL13P1.170 (PF13_0019’s neighbor gene)/
nucleotidyltransferase, putative
Poly(A) RNA polymerase protein 2 (% of PlasmoDB protein
Covered: 32; % Identity: 31; P-value: 5.2  1029)
PVX_089950 (ADR gene: PfDHFR-TS)/bifunctional
dihydrofolate reductase-thymidylate synthase 1,
putative
PVX_089365 (PVX_089950’s neighbor gene)/
helicase, putative
Chromo domain-containing protein 1 (% of PlasmoDB
protein Covered: 32,% Identity: 35; P-value: 3.5  1075)
PVX_118100 (ADR gene: PfMDR2)/multidrug resistance
protein 2, putative
PVX_099360 (PVX_118100’s neighbor gene)/
gamma-glutamylcysteine synthetase, putative
Glutamate–cysteine ligase (% of PlasmoDB protein
Covered: 63;% Identity: 32; P-value: 7.6  1064)
The list of selected SL gene pairs is shown in this table. Potential antimalarial drug targets (inferred SL partners for ADR genes) are suggested for future experimental
validation. All SL genes represented in this table do not have any human homologous gene. For application to yeast drugs provided by the FitDB, we conjectured the possibility
of evolutionary conservation between the yeast genes and Plasmodium homologs by identifying similarities in protein chains in the Protein Data Bank. The ﬁve drug target
genes are also shown in Fig. 5.
Fig. 5. Inferred Plasmodium SL gene networks to select antimalarial drug targets. To narrow down the list of drug target candidates, potential antimalarial drug target genes
are suggested for future experimental validation. The resulting network was ﬁltered by identifying protein similarities in the PDB provided by the PlasmoDB. In three
networks, all the ﬁltered inferred Plasmodium SL pairs (ADR genes and their inferred SL partners) do not include human orthologs except for some ADR genes such as
PFD0830w, PVX_089950, and PB000415.02.0. These ADR genes and their SL partners extracted from the inferred Plasmodium SL gene network can serve as alternative
antimalarial drug targets for malaria patients with ADR genes. In addition, we conjectured the possibility of evolutionary conservation between the yeast genes and
Plasmodium homologs through the identiﬁcation of protein similarities. We then obtained the ﬁve inferred SL partners (marked by red loops) having the inferred Plasmodium
SL gene networks, which exhibit protein similarities among the yeast orthologs and Plasmodium orthologs. (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
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ness data for the yeast homologs of the selected Plasmodium SL
genes to ﬁnd new drugs for clinical malaria treatment.
All Plasmodium genes summarized in Tables 1–3 are not human
orthologs except for ADR genes such as PFD0830w, PVX_089950 and
PB000415.02.0. Hence, the selective mutation of the SL genes might
have strong therapeutic potential in malaria elimination.4. Discussion
In the present study, a methodology based on the SL relation of
genes is proposed to select drug targets and drug candidates for
human antimalarial therapy and for experimental validation. A
simple computational tool was established to identify SL genes as
proper drug targets by analyzing the inferred SL genes of
Plasmodium species (P. falciparum and P. vivax for human malarial
therapy, and P. berghei for an in vivo experimental model). The in-
ferred Plasmodium SL genes can be used to search for drug targetsfor effective antimalarial therapy through in vitro or in vivo exper-
iments. However, in vitro experiments on P. vivax are not easy to
perform. P. vivax can only be cultured in vitro for short periods
(at least partially due to this parasite’s preference for infecting
short-lived reticulocytes) and drug studies must therefore be per-
formed at sites where P. vivax is readily available. In addition,
genetic manipulation of this parasite is virtually impossible (Eisen-
stein, 2012). The lack of good experimental models is another lim-
iting factor. Alternatively, the inferred P. berghei target genes can
be used for in vivo tests. Commercial drug candidates can eliminate
malaria parasites, but they are toxic for people with mutating hu-
man genes.
The incomplete effectiveness of a speciﬁc antimalarial drug in a
certain patient results from the mutation of one of the ADR genes.
To ensure successful therapy for these patients, the ﬁrst neighbors
of the mutated ADR gene should be the target of antimalarial ther-
apy such as chemical therapy with SL gene-speciﬁc drugs. If the
mutation of the ADR genes coincides with the mutation of their
SL partners, the malaria parasites would die. However, deﬁnitive
Fig. 6. Relationship between the biological processes of the PFE0195W and PF13_0019 genes. We conducted statistical GO analysis on the biological function of the selected
antimalarial drug target genes using BINGO 2.44. Using this GO term network (BINGO graph), the biological process of the PFE0195W and PF13_0019 genes were compared.
The BINGO graph visualizes the GO categories that are statistically over-represented in the context of the GO hierarchy. The PFE0195W and PF13_0019 genes are the ADR
genes and their ﬁrst-neighbor genes inferred from yeast SL pairs. The gene pair is one of the inferred SL gene pairs that contain the most potential malaria drug target genes.
For each circle, the GO term related to the biological process and the P value on the two corresponding genes are speciﬁed. The P value is a good indicator for the prominence
of a given functional category; white, yellow, and orange denote the different P value scales. The uncolored nodes are not over-represented; they are the parents of over-
represented categories at downstream (biological process in white box). Yellow nodes represent GO categories that are signiﬁcantly over-represented. For more signiﬁcant P
values, the saturation of the node color becomes denser (color legend panel). Blue arrows denote the stage and direction of biological processes. The GO term and P value are
shown in each white box. Purple represents the biological processes that are related only to the two genes. Monovalent inorganic cation transport, metal ion transport, and
sodium ion transport are biological processes that are related only to the PF13_0019 gene. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
Table 3
New malarial drug candidates.
Inferred Plasmodium SL genes
(Description)
Yeast homologs of
Plasmodium
Heterozygous knockout drug
(Description)
Homozygous knockout drug
(Description)
PB000415.02.0
(ADR gene: PfDHFR-TS)
YOR074C 5-Fluorouridine (antineoplastic), ﬂoxuridine (antiviral) x
PB000779.01.0
(PB000415.02.0’s neighbor
gene)
YDR334W Caspofungin (antifungal) Mechlorethamine (alkylating)
PFD0830w
(ADR gene: PfDHFR-TS)
YOR074C Methotrexate (antineoplastic antimetabolite),
5-ﬂuorouridine (antineoplastic), ﬂoxuridine (antiviral)
x
PF08_0048
(PFD0830w’s neighbor gene)
YDR334W Caspofungin (antifungal) Mechlorethamine (alkylating)
PF13_0019
(ADR gene: PfNHE1)
YHR081W Miconazole (antifungal), ﬂuconazole (antifungal),
fenpropimorph (antifungal)
x
MAL13P1.170
(PF13_0019’s neighbor gene)
YOL115W 5-ﬂuorouracil (antineoplastic antimetabolite), 5-
ﬂuorouridine (antineoplastic)
x
PVX_089950
(ADR gene: PfDHFR-TS)
YOR074C Methotrexate (antineoplastic antimetabolite),
5-ﬂuorouridine (antineoplastic), ﬂoxuridine (antiviral)
x
PVX_089365
(PVX_089950’s neighbor gene)
YLR085C Alverine citrate (psychoactive) Mechlorethamine (alkylating), busulfan
(alkylating)
PVX_118100
(ADR gene: PfMDR2)
YMR301C Fluconazole (antifungal) x
PVX_099360
(PVX_118100’s neighbor gene)
YJL101C Itraconazole (antifungal), methotrexate (antineoplastic
antimetabolite)
x
In future antimalarial drug research, a couple of the best candidates must be selected from the list, and they should be experimentally demonstrated to have the desired effect
on the parasite. Drug target candidates were ﬁnally selected from ADR genes and their SL partners containing inferred Plasmodium (P. falciparum, P. vivax, and P. berghei) SL
genes. We analyzed the ﬁtness data for the yeast homologs of the selected Plasmodium genes to ﬁnd new drugs for clinical malaria treatment. The right column of this table
shows which drugs obtained from the top three experiments can be searched in the Drug Bank database.
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history and different architectures of yeast and Plasmodium
genomes.
The evolutionary conservation of SL pairs is controversial (Tar-
ailo et al., 2007; Yuen et al., 2007; Dixon et al., 2008; Tischler et al.,
2008), although a signiﬁcant conservation of SL interactions be-
tween eukaryotes has been studied (Dixon et al., 2008). Not allyeast SL gene pairs are conserved in distantly related organisms.
However, previous studies have reported SL genes conserved from
yeast. For instance, the evolutionary conserved gene MHO1 is syn-
thetic lethal with PLC1 (Schlatter et al., 2012).
P-type ATPase 3 seems to have no merit as a drug target be-
cause the gene has been proposed as a target by other researchers
(Rozmajzl et al., 2001). Therefore, we regarded the PfATP3
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when its SL partner mutates.
The drug may have an adverse effect on Plasmodium but not on
human cells. To avoid such unwanted side effects on human hosts,
parasitic enzymes should be targeted instead of homologous hu-
man enzymes (Yeh et al., 2004). If the homologs of drug target
genes exist in humans, the enzyme would neither be essential to
the human host nor have different inhibitory effects because of
their different protein structure and regulation.
Potential drug target genes have to be expressed in some or all
of the developmental stages of parasites. We do not know the
developmental stage at which the effect of the drug therapy would
appear. However, we conjectured that the therapeutic effect would
be better when the expressed SL genes in some of the developmen-
tal stages of the parasites are simultaneously targeted. Provisional
drug targets can be examined computationally and experimentally
to extract these features. Experimental analyses can be performed
under in vitro and in vivo conditions for Plasmodium, but such
experimental studies are costly and laborious. Comparisons be-
tween the present predictions with such experimental data would
be particularly interesting.
Homology data provide important information that can be
used to predict the functions of unknown proteins of closely re-
lated species. A large number of gene or protein sequences are
stored in many databases, but the functions of the majority of
these proteins are unknown. An experimental analysis for all of
them is almost impossible (Itoh et al., 2004). Thus, computational
methods to predict protein functions are commonly adopted, and
homology searching is the most efﬁcient and prevalent means
(Itoh et al., 2004). Interestingly, all of the selected genes express
protein products with interrelated biological functions, such as
ATPase and ion transportation. Thus, ADR genes and their partners
with these functions can reasonably be expected to give SL inter-
actions. In this study, we conjectured that the key metabolic path-
ways, housekeeping functions, and repertoire of predicted
membrane transporters were highly conserved between the P. vi-
vax and P. falciparum proteomes (Gardner et al., 2002). Conse-
quently, the two species had similar metabolic potentials
(Carlton et al., 2008). We surveyed the ﬁtness data for the homo-
log yeast genes of the selected genes to ﬁnd new drugs for clinical
malaria treatment. In this survey, the yeast chemogenomic assays
were used to predict its therapeutic potential in malaria (Hillen-
meyer et al., 2010). The proposed drug candidates were searched
in the DrugBank 3.0 database, which contains comprehensive
information on the target diseases, proteins, genes, and organisms
on which these drugs act. Researchers can obtain helpful informa-
tion from the DrugBank database to verify a speciﬁc antimalarial
therapy for the proposed antimalarial drug candidates. Some of
the drug candidates in Table 3, such as methotrexate, ﬂuoxuri-
dine, mechlorethamine, ﬂuorouracil, alverine, busulfan, and
miconazole, have inﬂuence on humans. If these drugs are to be
used as antimalarial drugs, the severity of their side effects should
be checked. A drug can bind to a human protein even if it is not a
close analogue of the parasite target, as long as the two have a
strong similarity in their ligand-binding domains. Among the list
of drug candidates in Table 3, caspofungin and itraconazole are
worthwhile for drug screening because there is no report on tox-
icity or effect on the human organism for these two drugs. No sig-
niﬁcant lethality was observed when itraconazole was
administered orally to mice and rats. Therefore, based on previous
studies, we suggest a new methodology for antimalarial therapy.
This methodology provides not only new potential gene
candidates for further experimental tests and for drug design by
supplying suitable Plasmodium SL gene pairs that can be used as
a potential basis for future pharmacologic tests, but also informa-
tion on new usage for existing drugs.5. Conclusions
Taking a speciﬁc antimalarial drug is not always effective for
some patients because of the mutation of ADR genes in malaria
parasites. To solve this problem, we proposed a novel approach
for searching for pertinent antimalarial drug targets based on the
identiﬁcation of SL pairs of proteins with ADR genes. We suggested
a new concept of antimalarial therapy using data integration and
inference by homology analysis of yeast–human–Plasmodium. Po-
tential antimalarial drug targets and drug candidates were sug-
gested for future experimental validation. ADR genes and their
ﬁrst neighbors extracted from the inferred Plasmodium SL gene
networks can be used as alternative antimalarial drug targets for
a malaria parasite with ADR genes. The inference of SL gene pairs
in Plasmodium and humans was described based on yeast SL gene
data. Yeast SL interaction data as well as homologous information
on Plasmodium, human, yeast, and ADR genes were integrated to
provide a list of candidate genes for malarial therapy. The proposed
candidates can be used as drug targets in antimalarial therapy for
future experimental validation. If one gene of a Plasmodium SL gene
pair has a mutation that causes ADR, the drug targeted at another
gene can be used for effective therapy with largely reduced injury
to human cells.
The Plasmodium cells can be killed, while keeping the human
cells intact by mutating or blocking the SL partner of the mutated
gene that causes ADR. SL gene pairs have been used to kill malaria
parasites selectively and leave human cells unharmed. The present
SL screening analysis and the use of highly curated databases are
very helpful for discovering proper drugs and identifying correct
gene targets in antimalarial research. In conclusion, the present
computational approach is inexpensive and very simple to adopt.
The approach also has strong potential in the preparation of chem-
ical therapy with SL gene-speciﬁc chemical drugs or gene therapy
and can help identify suitable drug candidates with apparent anti-
malarial function for clinical malaria treatments.
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